Plaque disruption and thrombosis in unstable angina pectoris.
Therapeutic strategies and clinical trials in unstable angina should be based on the pathogenesis, risk, and mechanisms of thrombosis. The mechanisms of thrombosis and the differences in the effects of anticoagulant, antithrombotic, antifibrin, and antiplatelet drugs must be taken into account when determining the dosage and duration of therapy. Ignoring these principles may prevent identification of new therapy, increase the cost of new drug development and research, increase the cost of new drugs, and increase the cost of medical care.
Chesebro
J H
JH
Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905.
Zoldhelyi
P
P
Fuster
V
V
D000789:Angina, Unstable / Q000503:physiopathology / Q000628:therapy*; D000818:Animals; D006462:Hemolytic Plaque Technique; D006801:Humans; D012212:Rheology; D015912:Thrombolytic Therapy; D013927:Thrombosis / Q000503:physiopathology*; D014661:Vasoconstriction / Q000502:physiology